F. Stephen Hodi - Concepedia

Author

F. Stephen Hodi

Also Known As

F Hodi, F S Hodi, F Stephan Hodi, F Stephen HODI, F Stephen Hodi, F Stephen. Hodi, F. Hodi, F. S. Hodi, F. STEPHEN HODI, F. Stephen Hodi

1.5K

Publications

160.1K

Citations

155

H-Index

187

Concepts

All Affiliations

Dana-Farber Cancer Institute Brigham and Women's Hospital Harvard University Memorial Sloan Kettering Cancer Center Massachusetts General Hospital

About

F. Stephen Hodi is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	78	226	44.9K
2	Health Sciences	33	54	7.5K
3	Engineering	6	6	1.4K
4	Law	1	1	1.8K
5	Administrative Law	1	1	1.8K

F. Stephen Hodi

438

Publications

143.8K

Citations

140

H-Index

Page 1

	Year	Citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma F. Stephen Hodi, Steven O’Day, David F. McDermott, New England Journal of Medicine	2010	14.9K
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, New England Journal of Medicine	2012	12.5K
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2015	8K
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2017	5.3K
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Nature MedicineBiomarker TargetAnti-pd-l1 Antibody Mpdl3280aImmunologyPathology	2014	5.2K
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma James Larkin, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2019	3.6K
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Omid Hamid, Caroline Robert, Adil Daud, New England Journal of Medicine	2013	3.4K
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria Jedd D. Wolchok, Axel Hoos, Steven O’Day, Clinical Cancer Research	2009	3.2K
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma Michael A. Postow, Jason Chesney, Anna C. Pavlick, New England Journal of Medicine	2015	2.7K
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, The Lancet Oncology Checkmate 037MedicineMelanomaNivolumab Versus ChemotherapyImmune Checkpoint Inhibitor	2015	2.6K

Page 1